MSD-ERTUGLIFLOZIN-METFORMIN 2.5/500 ertugliflozin/metformin hydrochloride 2.5 mg/500 mg film-coated tablet blister pack

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

metformin hydrochloride, Quantity: 500 mg; ertugliflozin pyroglutamic acid, Quantity: 3.238 mg (Equivalent: ertugliflozin, Qty 2.5 mg)

Verfügbar ab:

Merck Sharp & Dohme (Australia) Pty Ltd

Darreichungsform:

Tablet, film coated

Zusammensetzung:

Excipient Ingredients: microcrystalline cellulose; Carnauba Wax; povidone; sodium lauryl sulfate; magnesium stearate; crospovidone; titanium dioxide; hypromellose; hyprolose; iron oxide red

Verabreichungsweg:

Oral

Einheiten im Paket:

56, 14

Verschreibungstyp:

(S4) Prescription Only Medicine

Anwendungsgebiete:

MSD-ERTUGLIFLOZIN-METFORMIN (ertugliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and metformin is appropriate. [see 5.1 PHARMACODYNAMIC PROPERTIES, Clinical trials and 4.2 DOSE AND METHOD OF ADMINISTRATION]

Produktbesonderheiten:

Visual Identification: Pink, oval, film-coated tablets debossed with '2.5/500' on one side and plain on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 2 Years; Container Temperature: Store below 30 degrees Celsius

Berechtigungsstatus:

Licence status A

Berechtigungsdatum:

2018-05-17